Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.
作者:
主题词
人类(Humans);多发性骨髓瘤(Multiple Myeloma);Ikaros转录因子(Ikaros Transcription Factor);沙立度胺(Thalidomide);泛素蛋白连接酶类(Ubiquitin-Protein Ligases);抗肿瘤药(Antineoplastic Agents);分子靶向治疗(Molecular Targeted Therapy);临床试验(主题)(Clinical Trials as Topic);动物(Animals);哌啶酮类(Piperidones);吗啉类(Morpholines);受体, 白细胞介素17(Receptors, Interleukin-17);衔接蛋白质类, 信号转导(Adaptor Proteins, Signal Transducing);苯邻二甲酰亚胺类(Phthalimides)
DOI
10.1080/17474086.2024.2382897
PMID
39054911
发布时间
2024-08-01
- 浏览0

Expert review of hematology
445-465页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文